Find and Pitch Jounalists, Get Your Story Covered

Tags: metformin dementia opioid methadone tobacco

	Profile	Recent Articles on Subject
1	Kristen Monaco MedPage Today	Imcivree Label Expanded; Weight Loss With Weekly Injection; Kidney Donation Chain - about 1 month ago Zepbound Can Prevent Diabetes; Menopause and Cognition; Tandem's Insulin Pump Update - 5 months ago Early-Stage GLP-1 Win in Obesity; An Argument for BMI's Value; Insulin Supply Issues - 6 months ago FDA Approves First-Ever Drug for Serious Liver Condition - 11 months ago More Mounjaro Doses Limited; At-Home Menopause Tests? Kimchi for Lower Obesity Risk - 12 months ago One Class of Antidiabetic Linked With Lower Kidney Stone Risk - about 1 year ago Breast Cancer Drug Repurposed for Infant With Congenital Hyperinsulinism - about 1 year ago In Acute Kidney Disease, SGLT2 inhibitors Were All-Around Protective - about 1 year ago Phase II Wins, Losses for Obesity Drugs; More Positive Veozah Data; Walking Off T2D - about 1 year ago Methotrexate Tied to Greater Risks for Older Patients With CKD - about 1 year ago Mounjaro vs Ozempic for Obesity; New Microwave Ablation System; GAHT Erythrocytosis - about 1 year ago Glucose Supplement Recalled; ADA Sued by Former Employee; Forteo Generic OK'd - about 1 year ago Another Study Highlights Metformin's Dementia Protection Properties - over 1 year ago Hospitalizations With Fake Ozempic; Vosoritide OK'd for All Ages; Mounjaro for Kids? - over 1 year ago Farxiga Cuts A1c in Pediatric Diabetes; Late-Stage CAH Win; At-Home Menopause Test - over 1 year ago Smoking-Related Metabolic Changes Partly Drive Type 2 Diabetes Risk - over 1 year ago Faster-Acting Insulin Aspart Safe for Pregnant Women With Diabetes - over 1 year ago
2	Ed Silverman STAT News Pharmalot columnist. Senior writer at STATnews. pharmaceutical industry	STAT+: Pharmalittle: We’re reading about a Merck deal for an obesity pill, a departing FDA official, and more - about 1 month ago STAT+: Pharmalittle: We’re reading about a Merck drug-label controversy, Astellas pulling an application, and more - 3 months ago STAT+: Pharmalittle: We’re reading about Zepbound trial results, an Alnylam heart drug, and more - 5 months ago STAT+: Pharmalittle: We’re reading about Roche obesity drug data, fallout from the Menendez verdict, and more - 7 months ago STAT+: Pharmalittle: We’re reading about a Pfizer daily weight loss pill, a Novo Nordisk setback, and more - 7 months ago STAT+: Pharmalittle: We’re reading about Wegovy approved for heart risks, an ALS drug puzzle, and more - 11 months ago STAT+: Pharmalittle: We’re reading about Ozempic tackling kidney disease, OTC birth control, and more - 11 months ago STAT+: Pharmalittle: More U.S. states and cities are suing insulin makers; Biden looks to boost U.S. drug manufacturing amid shortages - about 1 year ago STAT+: Pharmalittle: Lilly wins FDA approval for a weight-loss drug; AstraZeneca enters the race for an obesity pill - about 1 year ago STAT+: Pharmalittle: Sarepta Duchenne therapy misses primary endpoint; FDA holds panel for first CRISPR treatment for sickle cell - over 1 year ago STAT+: Pharmalittle: Novo halts Ozempic kidney failure trial after early signs of success; GSK settles California Zantac lawsuit - over 1 year ago
3	Marissa Plescia MedCity News Reporter at MedCity News. reportingjournalism	Noom Launches Oral Medication Offering for Weight Loss - about 2 months ago
4	Ian Ingram MedPage Today Deputy Managing Editor. MedPage Today. New York, New York medical journalismediting	GLP-1 Drugs Tied to Reduced Risk of Dangerous Blood Clots - about 2 months ago
5	The Conversation Science Alert Science news. Official account. Australia science news	Ozempic vs Supplements: Dietitian Reveals Truth About GLP-1 Imitations - 2 months ago Type 2 Diabetes Drug Linked to 35% Lower Dementia Risk in Patients - 5 months ago
6	Gillian Booth MedPage Today Singer, social media manager. Philadelphia, Pennsylvania social mediamusic	IG Live December 2: The Weight of Wegovy - 2 months ago
7	Mike Bassett MedPage Today Explains healthcare complexities. Not endorsements. New York, New York Healthcare journalism	Novel Therapy Reduced Liver Fat, Improved Fibrosis in MASH - 2 months ago FDA Panel Rejects SGLT1/2 Inhibitor for Type 1 Diabetes - 3 months ago Weight-Loss Drug Overdoses; Record Number of Retracted Studies; Yoga and Cadavers - about 1 year ago
8	Sophie Putka MedPage Today Enterprise, investigative writer. New York, USA enterprise journalisminvestigative journalism	Metformin Use Linked to Fewer Asthma Attacks - 2 months ago
9	Elaine Chen STAT News Reporter at STATnews. Formerly at Business Insider. Chicago, Illinois journalism	STAT+: With new Wegovy data in hand, Novo Nordisk will file for approval in MASH - 3 months ago STAT+: Lilly’s Zepbound slashed risk of developing diabetes - 5 months ago STAT+: Positive trial results set up obesity drug Wegovy for use against heart failure - 10 months ago Eli Lilly gets FDA approval to sell Mounjaro as obesity drug called Zepbound - about 1 year ago
10	Ashley Gallagher, Associate Editor Pharmacy Times One of Cabra girls on GoggleboxIRL. Dublin City, Ireland televisionentertainment	Some Disease Burden of Obesity Requires Pharmacotherapy, Not Just Lifestyle Interventions - 3 months ago FDA Grants Breakthrough Device Designation for System Maintaining Weight Loss After GLP-1 - 6 months ago Intermittent Fasting and Meal Replacements Improved Short-Term Glycemia - 6 months ago Tirzepatide Shows Improvements in MASH Without Worsening Fibrosis - 7 months ago INHALE-3 Study Data Shows Diabetes Care Is Not “One-Size-Fits-All” - 7 months ago Teva Launches Generic Formulation of Liraglutide in US - 7 months ago FLOW Trial Results Demonstrate Positive Kidney Outcomes With Semaglutide - 11 months ago Proposed Biosimilar Liraglutide Shows Non-Inferiority to Reference Drug for Type 2 Diabetes - about 1 year ago Metformin Cessation Has Been Associated With Increased Dementia Incidence - about 1 year ago

Journalists covering metformin